Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for shares of Stoke Therapeutics in a report issued on Wednesday, March 19th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.53) per share for the quarter. HC Wainwright has a "Buy" rating and a $47.00 price objective on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics' Q2 2025 earnings at ($0.54) EPS.
Several other research firms have also issued reports on STOK. Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Chardan Capital reaffirmed a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, March 18th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $23.00.
Get Our Latest Stock Analysis on STOK
Stoke Therapeutics Stock Performance
Stoke Therapeutics stock traded up $0.14 during midday trading on Thursday, reaching $8.29. 964,265 shares of the company's stock were exchanged, compared to its average volume of 840,350. Stoke Therapeutics has a 52 week low of $6.29 and a 52 week high of $17.58. The stock's 50-day simple moving average is $9.46 and its 200 day simple moving average is $11.35. The firm has a market cap of $448.31 million, a price-to-earnings ratio of -3.95 and a beta of 0.99.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million.
Institutional Trading of Stoke Therapeutics
Institutional investors have recently modified their holdings of the company. Intech Investment Management LLC purchased a new stake in Stoke Therapeutics in the third quarter valued at $160,000. Charles Schwab Investment Management Inc. raised its position in Stoke Therapeutics by 9.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company's stock valued at $3,885,000 after purchasing an additional 26,870 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company's stock worth $936,000 after acquiring an additional 71,647 shares during the last quarter. Checkpoint Capital L.P. purchased a new position in Stoke Therapeutics during the 3rd quarter valued at about $1,936,000. Finally, RTW Investments LP raised its stake in shares of Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock valued at $57,177,000 after acquiring an additional 427,447 shares in the last quarter.
Insiders Place Their Bets
In related news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now owns 63,962 shares of the company's stock, valued at approximately $554,550.54. This trade represents a 5.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,532 shares of company stock valued at $143,332. Company insiders own 11.30% of the company's stock.
About Stoke Therapeutics
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
See Also
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
